ReviewNutrients2023
Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review.
Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Development and Characterization of Intravenous Nanoemulsions Loaded withMolecules (Basel, Switzerland) · 2026Article
- Lutein Modulates Stress-Responsive Signaling Pathways in THLE-2 Human Hepatocytes Under Intestinal Failure-Associated Liver Disease Conditions.Molecules (Basel, Switzerland) · 2026Article
- Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial.Clinical pharmacology in drug development · 2026Article
- Mechanistic Analysis of Fisetin in Liver Diseases and Its Potential Therapeutic Application in IFALD-A Review of In Vitro and In Vivo Studies.Nutrients · 2025Review
- Liver injury in a preclinical model of short bowel syndrome is associated with impaired autophagy.Scientific reports · 2025Article
- 100% Fish oil-based lipid emulsion inhibits hepatic stellate cell activation via suppression of the TGF-β1 autocrine signaling.Human cell · 2025Article
- Harnessing algae oil as a sustainable DHA source for parenteral nutrition in vegan patients.Scientific reports · 2025Article
- Review
- Curcumin: A Natural Warrior Against Inflammatory Liver Diseases.Nutrients · 2025Review
- Pathogenesis and Management of Intestinal Failure-Associated Liver Disease.Seminars in liver disease · 2025Review
- Assessment of liver stiffness and steatosis in patients with intestinal failure: a cross-sectional study.Frontiers in nutrition · 2025Article
- Investigation of parenteral nutrition-induced hepatotoxicity using human liver spheroid co-cultures.Archives of toxicology · 2024Article
- Acquired Zinc Deficiency in Preterm Infant Post-Surgery for Necrotizing Enterocolitis (NEC) on Prolonged Total Parenteral Nutrition (TPN).Pediatric reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal failure-associated liver disease (IFALD) is a spectrum of liver disease including cholestasis, biliary cirrhosis, steatohepatitis, and gallbladder disease in patients with intestinal failure (IF). The prevalence of IFALD varies considerably, with ranges of 40-60% in the pediatric population, up to 85% in neonates, and between 15-40% in the adult population. IFALD has a complex and multifactorial etiology; the risk factors can be parenteral nutrition-related or patient-related. Because of this, the approach to managing IFALD is multidisciplinary and tailored to each patient based on the etiology. This review summarizes the current knowledge on the etiology and pathophysiology of IFALD and examines the latest evidence regarding preventative measures, diagnostic approaches, and treatment strategies for IFALD and its associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.